Revenue from operations stood at Rs 1909 crore in Q2 FY24, up 2.91% from Rs 1855 crore recorded in the similar quarter previous year.

Total income grew by 3.1% year on year to Rs 1,995 crore in the quarter ended 30 September 2023.

Profit before tax dropped 23.74% to Rs 469 crore in Q2 FY24 as compared with Rs 615 crore posted in Q2 FY23.

Total expense in Q2 FY24 stood at Rs 1,526 crore, registering a growth of 15.61% YoY. Cost of material consumed was at Rs 711 crore (down 12.97% YoY) while employee benefit expenses stood at Rs 266 crore (up 14.66% YoY) during the period under review.

On a standalone basis, the company net profit tumbled 29.77% to Rs 342 crore despite of 2.47% rise in revenue to Rs 1,868 crore in H1 FY24 over H1 FY23.

Forex gain for the current quarter amounted to Rs 10 crore as against a gain of Rs 30 crore during the corresponding quarter of the last year.

Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.